Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J0ZS
|
|||
| Former ID |
DAP000665
|
|||
| Drug Name |
Gabapentin
|
|||
| Synonyms |
Aclonium; GBN; Gabapen; Gabapentina; Gabapentine; Gabapentinium; Gabapentino; Gabapentinum; Gabapetin; Neurontin; Serada; Vultin; Apotex brand of gabapentin; Aventis brand of gabapentin; Gabapentin GR; Gabapentin Hexal; Gabapentin Stada; Gabapentino [Spanish]; Hexal brand of gabapentin; Novopharm brand of gabapentin; Parke Davis brand of gabapentin; Pfizer brand of gabapentin; Pharmascience brand of gabapentin; Ratiopharm brand of gabapentin; Stadapharm brand of gabapentin; GOE 2450; Go 3450; Apo-Gabapentin; DDS-2003; DM-1796; DM-5689; G-154; Gabapentin (Neurontin); Gabapentin-ratiopharm; Gabapentine [INN-French]; Gabapentino [INN-Spanish]; Gabapentinum [INN-Latin]; Goe-3450; Neurontin (TN); Novo-Gabapentin; PMS-Gabapentin; Warner-Lambert brand of gabapentin; Gabapentin [USAN:INN:BAN]; [1-(AMINOMETHYL)CYCLOHEXYL]ACETIC ACID; Gabapentin (JAN/USAN/INN); 1-(Aminomethyl)-cyclohexaneacetic acid; 1-(Aminomethyl)cyclohexaneacetic acid; 2-[1-(aminomethyl)cyclohexyl]acetic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Complex partial seizure [ICD-11: 8A68.0; ICD-9: 345.4, 345.5] | Approved | [1], [2] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 3 | [1], [3] | ||
| Therapeutic Class |
Analgesics
|
|||
| Company |
Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C9H17NO2
|
|||
| Canonical SMILES |
C1CCC(CC1)(CC(=O)O)CN
|
|||
| InChI |
1S/C9H17NO2/c10-7-9(6-8(11)12)4-2-1-3-5-9/h1-7,10H2,(H,11,12)
|
|||
| InChIKey |
UGJMXCAKCUNAIE-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 60142-96-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
855579, 3206533, 5651496, 7847398, 7887769, 7979342, 8028266, 8028269, 8152192, 10321252, 11111218, 11112806, 11113327, 11466889, 11468009, 11486558, 11528594, 12012796, 15171186, 17405144, 24278159, 25623436, 29222580, 46506529, 47291223, 47365305, 47515412, 47589087, 48035236, 48413201, 48416046, 49655262, 49698669, 49833701, 50100248, 50103936, 50103937, 50519620, 53777688, 56312982, 56365854, 57321804, 85174424, 85209452, 85231060, 87560508, 89649772, 90340599, 91146476, 92125867
|
|||
| ChEBI ID |
CHEBI:42797
|
|||
| ADReCS Drug ID | BADD_D00981 | |||
| SuperDrug ATC ID |
N03AX12
|
|||
| SuperDrug CAS ID |
cas=060142963
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Gamma-aminobutyric acid B receptor (GABBR) | Target Info | Antagonist | [4] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| GABAergic synapse | ||||
| Estrogen signaling pathway | ||||
| Morphine addiction | ||||
| Reactome | Activation of G protein gated Potassium channels | |||
| G alpha (i) signalling events | ||||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | ||||
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | ||||
| WikiPathways | GPCRs, Class C Metabotropic glutamate, pheromone | |||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | ||||
| Potassium Channels | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5483). | |||
| REF 2 | Use of second-generation antiepileptic drugs in the pediatric population. Paediatr Drugs. 2008;10(4):217-54. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 4 | Gabapentin increases a tonic inhibitory conductance in hippocampal pyramidal neurons. Anesthesiology. 2006 Aug;105(2):325-33. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.